

PCT  
PATENT

Atty. Docket No. PP-18521.004

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 22, 2005.

By: Jeanne Lupton  
Jeanne Lupton**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Derek O'Hagan et al.

U.S. Application No. 10/505,250

International Application No.: PCT/US03/05017

International Filing Date: February 20, 2003

Group Art Unit: Unassigned

Examiner: Unassigned

Confirmation No.: 7392

For: MICROPARTICLES WITH ADSORBED POLYPEPTIDE-CONTAINING MOLECULES

**INFORMATION DISCLOSURE STATEMENT  
TRANSMITTAL**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is an Information Disclosure Statement and accompanying Form PTO-1449 for the above-identified patent application.

☒ In accordance with 37 C.F.R. §1.97(b), no additional fee for submission of the IDS is required.


☐ In accordance with 37 C.F.R. §1.97(c), also enclosed is:

☐ the fee of \$180.00 as set forth in 37 C.F.R. 1.17(p); or

- ☐ a statement as specified in 37 C.F.R. §1.97(e).
- ☐ In accordance with 37 C.F.R. §1.97(d), a statement as specified in 37 C.F.R. §1.97 (e) and the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) are also enclosed.
- ☐ Check No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ for total fee is attached.
- ☒ A return receipt postcard is also enclosed.
- ☐ Please charge \$ \_\_\_\_\_ to Deposit Account No. 03-1664 for the total fee. This paper is being submitted in duplicate.

The Commissioner for Patents is hereby authorized to charge any additional fees (or credit any overpayment) associated with this communication and which may be required under 37 CFR 1.16 and 1.17 to Deposit Account No. 03-1664.

Respectfully submitted,

By:   
Helen Lee  
Reg. No. 39,270

Date: June 22, 2005

CHIRON CORPORATION  
Intellectual Property Dept.  
4560 Horton Street  
Emeryville, CA 94608-2916  
Telephone: (510) 923-2192  
Facsimile: (510) 655-3542

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on Aug 22, 2005.

By: \_\_\_\_\_

Jeanne Lupton

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:           Derek O'Hagan et al.

U.S. Application No.           10/505,250

International Application No.: PCT/US03/05017

International Filing Date:   February 20, 2003

Group Art Unit:               Unassigned

Examiner:                      Unassigned

Confirmation No.:             7392

For:   MICROPARTICLES WITH ADSORBED POLYPEPTIDE-CONTAINING MOLECULES

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §1.56 AND §1.97(b)(3)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:


The citations listed on the enclosed Information Disclosure Form PTO-1449 may be material to the examination of the above-identified patent application. Therefore, Applicant submits these documents in compliance with the duty of disclosure as defined in 37 C.F.R. §1.56 and §1.97(b)(3). The Examiner is requested to make these citations of official record in the present applications.

The present Information Disclosure Statement is being filed before the mailing date of the first Office action on the merits, and, therefore, no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required.

This Information Disclosure Statement under 37 C.F.R. §1.56 and §1.97(b)(3) is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these citations constitute prior art under 35 U.S.C. §102 or §103.

The Commissioner for Patents is hereby authorized to charge any additional fees (or credit any overpayment) associated with this communication and which may be required under 37 CFR 1.16 and 1.17 to Deposit Account No. 03-1664.

Respectfully submitted,

By:   
Helen Lee  
Reg. No. 39,270

Date: June 22, 2005

CHIRON CORPORATION  
Intellectual Property Dept.  
4560 Horton Street  
Emeryville, CA 94608-2916  
Telephone: (510) 923-2192  
Facsimile: (510) 655-3542

<b>IN THE UNITED STATES PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> UNDER 37 CFR §1.56, §1.97, AND §1.98  <b>PTO-1449 FORM (MODIFIED)</b>  <b>SHEET 1 OF 2</b>	ATTORNEY DOCKET NO. PP18521.004		SERIAL NO. 10/505,250 (PCT/US03/05017)	
	APPLICANTS: Derek O' Hagan et al.		EXAMINER: Unassigned	
	PCT FILING DATE: February 20, 2003	GROUP ART UNIT: Unassigned	CONFIRMATION NO. 7392	

U.S. PATENT DOCUMENTS							
Ex'r Initial	Ref. No.	Document No.	Date	Name	Class	Subclass	Filed
	A1	2002/0136776A1	September 26, 2002	Fang et al.			
	A2	5,858,410	January 12, 1999	Muller et al.			
	A3	6,383,470	May 7, 2002	Fritzsche et al.			

FOREIGN PATENT DOCUMENTS								
Ex'r Initial	Ref. No.	Document No.	Publication Date	Country	Class	Subclass	Translation YES NO	
	B1	WO 02/26209	April 4, 2002	WIPO				
	B2	WO 00/50006	August 31, 2000	WIPO				
	B3	WO 98/33487	August 6, 1998	WIPO				
	B4	WO 97/02810	January 30, 1997	WIPO				
	B5	WO 00/06123	February 10, 2000	WIPO				
	B6	WO 01/36599	May 25, 2001	WIPO				
	B7	WO 02/26212	April 4, 2002	WIPO				
	B8	WO 01/81609	November 1, 2001	WIPO				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ex'r Initial	Ref. No.	Description
	C1	M. Briones et al., "The Preparation, Characterization, and Evaluation of Cationic Microparticles for DNA Vaccine Therapy," <i>Pharmaceutical Research</i> , 18(5):709-712 (2001).

EXAMINER'S SIGNATURE	DATE CONSIDERED
† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. Include copy of this form in next communication to applicant.	
* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).	

<p align="center"><b>IN THE UNITED STATES PATENT AND TRADEMARK OFFICE</b></p> <p align="center"><b>INFORMATION DISCLOSURE STATEMENT</b></p> <p align="center"><b>UNDER 37 CFR §1.56, §1.97, AND §1.98</b></p> <p align="center"><b>PTO-1449 FORM (MODIFIED)</b></p> <p align="center"><b>SHEET 2 OF 2</b></p>	<p>ATTORNEY DOCKET NO.</p> <p>PP18521.004</p>		<p>SERIAL NO.</p> <p>10/505,250 (PCT/US03/05017)</p>	
	<p>APPLICANTS:</p> <p>Derek O' Hagan et al.</p>		<p>EXAMINER:</p> <p>Unassigned</p>	
	<p>PCT FILING DATE:</p> <p>February 20, 2003</p>	<p>GROUP ART UNIT:</p> <p>Unassigned</p>	<p>CONFIRMATION NO.</p> <p>7392</p>	

	C2	J. Kazzaz et al, "Novel Anionic Microparticles Are a Potent Adjuvant for the Induction of Cytotoxic T Lymphocytes Against Recombinant p55 Gag from HIV -1," <i>J. Controlled Release</i> , 67:347-356 (2000).
	C3	K.S. Denis-Mize et al., "Plasmid DNA Adsorbed onto Cationic Microparticles Mediates Target Gene Expression and Antigen Presentation by Dendritic Cells," <i>Gene Therapy</i> , 7:2105-2112 (2000).
	C4	H. Jeffrey et al., "The Preparation and Characterization of Poly(lactide-co-glycolide) Microparticles. II. The Entrapment of a Model Protein Using a (Water-in-Oil)-in-Water Emulsion Solvent Evaporation Technique," <i>Pharmaceutical Research</i> , 10(3):362-368 (1993).
	C5	D.T. O'Hagan et al., "Long-Term Antibody Responses in Mice Following Subcutaneous Immunization with Ovalbumin Entrapped in Biodegradable Microparticles," <i>Vaccine</i> , 11(9):965-969 (1993).
	C6	M. Singh et al, "Cationic Microparticles Are an Effective Delivery System for Immune Stimulatory CpG DNA," <i>Pharmaceutical Research</i> , 18(10):1476-1479 (2001).
	C7	M. Singh et al., "Cationic Microparticles: A Potent Delivery System for DNA Vaccines," <i>Proc. Natl Acad. Sci. USA</i> , 97(2):811-816 (2000).
	C8	M. Singh et al., "Mucosal Immunization with HIV-1 Gag DNA on Cationic Microparticles Prolongs Gene Expression and Enhances Local and Systemic Immunity," <i>Vaccine</i> , 20:594-602 (2002).
	C9	D. O'Hagan et al, "Induction of Potent Immune Responses by Cationic Microparticles with Adsorbed Human Immunodeficiency Virus DNA Vaccines," <i>J. Virol.</i> , 75(19):9037-9043 (2001).
	C10	Y.-I. Jeong et al., "Preparation of poly(DL-lactide-co-glycolide) nanoparticles without surfactant," <i>J. Appl. Polymer Sci.</i> , 80:2228-2236 (2001).
	C11	H.-J. Jeon et al., "Effect of solvent on the preparation of surfactant-free poly(DL-lactide-co-glycolide) nanoparticles and norfloxacin release characteristics," <i>Int. J. Pharm.</i> , 207:99-108 (2000).
	C12	I. Soriano et al., "Use of surfactants in polylactic acid protein microspheres," <i>Drug Develop. Indust. Pharm.</i> , 21(5):549-558 (1995).
	C13	C.-Y. Yang et al., "Encapsulating aspirin into a surfactant-free ethyl cellulose microsphere using non-toxic solvents by emulsion solvent-evaporation technique," <i>J. Microencapsulation</i> , 18(2):223-236 (2001).
	C14	Y. Kawashima et al., "Properties of a peptide containing DL-lactide/glycolide copolymer nanospheres prepared by novel emulsion solvent diffusion methods," <i>Eur. J. Pharm.</i> , 45:41-48 (1998).

EXAMINER'S SIGNATURE	DATE CONSIDERED
<p>† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. Include copy of this form in next communication to applicant.</p> <p>* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).</p>	